<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04597879</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A00183-36</org_study_id>
    <secondary_id>38RC20.014</secondary_id>
    <nct_id>NCT04597879</nct_id>
  </id_info>
  <brief_title>Impact of Severe Brain Injury on Neuro-vascular and Endothelial Regulation of Peripheral Microcirculation.</brief_title>
  <acronym>MicroTC</acronym>
  <official_title>Study of the Impact of Severe Brain Injury on the Neuro-vascular and Endothelial Regulation of Peripheral Microcirculation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe brain injury (SBI) is one of the world's leading causes of death and disability in&#xD;
      young adults, but its peripheral vascular consequences in humans are poorly understood.&#xD;
&#xD;
      This prospective, monocentric, pathophysiological study aims to investigate differences in&#xD;
      vasoreactivity in the anterior aspect of the contralateral forearm at the most injured&#xD;
      cerebral hemisphere between patients with severe head trauma and patients with severe trauma&#xD;
      without associated brain injury matched on sex and age (+/- 5 years).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe brain injury (SBI) is one of the world's leading causes of death and disability in&#xD;
      young adults.&#xD;
&#xD;
      Its impact on cerebral vascularization is well known. At the systemic level, it induces&#xD;
      transient dysfunctions that can develop into severe failures, even in cases of isolated SBI.&#xD;
      Studies on a mouse model of SBI show alterations in peripheral vascular reactivity that&#xD;
      persist over time and are linked to endothelial dysfunction, the mechanism of which is a&#xD;
      decoupling of endothelial NO synthase in a context of systemic inflammation. However, no data&#xD;
      are available regarding the peripheral vascular consequences of SBI in humans.&#xD;
&#xD;
      The main objective of this prospective, monocentric, pathophysiological study is to determine&#xD;
      whether the postocclusive hyperaemic response at the anterior surface of the contralateral&#xD;
      forearm to the most injured cerebral hemisphere differs between patients with severe brain&#xD;
      injury and patients with severe trauma without associated head injury matched on sex and age&#xD;
      (+/- 5 years), by studying the amplitude of post-occlusive hyperaemia (maximum amplitude&#xD;
      expressed as percentage of vasodilatation and area under the curve : AUC) as a function of&#xD;
      the group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Actual">August 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Post-occlusive hyperaemia</measure>
    <time_frame>0-60 days</time_frame>
    <description>Maximum amplitude expressed as percentage of vasodilation and area under the curve: AUC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-occlusive hyperaemia with local anesthesia</measure>
    <time_frame>0-60 days</time_frame>
    <description>Maximum amplitude expressed as percentage of vasodilation and area under the curve: AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Current-Induced Hyperaemia</measure>
    <time_frame>0-60 days</time_frame>
    <description>Area under the curve expressed as a percentage of the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Current-Induced Hyperaemia with local anesthesia</measure>
    <time_frame>0-60 days</time_frame>
    <description>Area under the curve expressed as a percentage of the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local thermal hyperaemia</measure>
    <time_frame>0-60 days</time_frame>
    <description>Maximum amplitude of the initial peak expressed as a percentage of the baseline and area under the curve of the delayed plateau.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local thermal hyperaemia with local anesthesia</measure>
    <time_frame>0-60 days</time_frame>
    <description>Maximum amplitude of the initial peak expressed as a percentage of the baseline and area under the curve of the delayed plateau.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow amplitude after local cooling</measure>
    <time_frame>0-60 days</time_frame>
    <description>Amplitude of initial vasoconstriction averaged over 1 min around the lowest flow value during the first 5 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient venous post-compression hyperaemia</measure>
    <time_frame>0-60 days</time_frame>
    <description>Area under the curve and percentage change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of vasoreactivity in patients with severe brain injury</measure>
    <time_frame>0-60 days</time_frame>
    <description>Extent of post-occlusive hyperaemia, current-induced hyperaemia, thermal hyperaemia and cold response in patients with severe brain injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of vasoreactivity in healthy subjects</measure>
    <time_frame>Study visit</time_frame>
    <description>Description of the magnitude of post-occlusive hyperaemia, current-induced hyperaemia, thermal hyperaemia and cold response in healthy subjects.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Severe Traumatic Brain Injury</condition>
  <condition>Trauma</condition>
  <arm_group>
    <arm_group_label>Severe traumatic brain injury</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe trauma without brain trauma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        -  Patients admitted for severe head trauma or severe trauma without associated severe&#xD;
             head trauma in intensive care at Grenoble University Hospital.&#xD;
&#xD;
          -  Healthy volunteers recruited through classified ads&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy volunteers :&#xD;
&#xD;
          -  Men and women, over 18 years of age&#xD;
&#xD;
          -  Affiliation to a social security scheme&#xD;
&#xD;
          -  Signed Consent&#xD;
&#xD;
        Patients with Severe Brain Injury :&#xD;
&#xD;
          -  Male and female, over 18 years of age&#xD;
&#xD;
          -  Isolated severe brain injury, defined by an initial Glasgow score less than or equal&#xD;
             to 8.&#xD;
&#xD;
          -  Affiliation to a social security scheme&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Severe traumatized patients without associated severe brain injury:&#xD;
&#xD;
          -  men and women, over 18 years of age&#xD;
&#xD;
          -  severe trauma, defined by an Injury Severity Score (ISS) â‰¥ 16.&#xD;
&#xD;
          -  absence of associated severe brain injury, defined by an initial Glasgow score less&#xD;
             than or equal to 8.&#xD;
&#xD;
          -  affiliation to or beneficiary of a social security scheme&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity to lidocaine and/or prilocaine or to amide type local anesthetics or&#xD;
             to any of the excipients of the cream.&#xD;
&#xD;
          -  History of axillary lymph node dissection, trauma or axillary surgery&#xD;
&#xD;
          -  Prohibited treatments and procedures :&#xD;
&#xD;
               -  In patients with head trauma: ongoing treatment with systemic vasodilators&#xD;
                  (calcium channel blocker, milrinone).&#xD;
&#xD;
               -  In healthy volunteers: no treatment will be authorized other than paracetamol,&#xD;
                  hormone supplementation (contraceptive pill, hormone therapy, thyroid hormones).&#xD;
&#xD;
          -  Pregnant, parturient or breastfeeding women&#xD;
&#xD;
          -  Subject in a period of exclusion from another study,&#xD;
&#xD;
          -  Person deprived of liberty by judicial or administrative decision, person subject to a&#xD;
             legal protection measure,&#xD;
&#xD;
          -  Subject having exceeded the annual compensation threshold for testing&#xD;
&#xD;
          -  Subject cannot be contacted in case of emergency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Luc Cracowksi, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Luc Cracowski, Pr</last_name>
    <phone>0476767856</phone>
    <phone_ext>0033</phone_ext>
    <email>JLCracowski@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manon Gabin, Intern</last_name>
    <phone>0476767575</phone>
    <phone_ext>0033</phone_ext>
    <email>mgabin@chu-grenoble.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Luc Cracowski, Pr</last_name>
      <phone>0476767856</phone>
      <phone_ext>0033</phone_ext>
      <email>JLCracowski@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Manon Gabin, Intern</last_name>
      <phone>0476767575</phone>
      <email>mgabin@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Luc Cracowski, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thibaut Trouve-Buisson, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enkelejda Hodaj, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire Cracowski, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manon Gabin, Intern</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain trauma</keyword>
  <keyword>Severe traumatic brain injury</keyword>
  <keyword>Microcirculation</keyword>
  <keyword>Speckle</keyword>
  <keyword>Post-occlusive reactive hyperaemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

